Sedation

DGAP-News: PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE FOR REMIMAZOLAM IN ITALIAN HOSPITAL

Retrieved on: 
Tuesday, June 2, 2020

PAION was contacted by the San Raffaele Hospital as to whether remimazolam could be delivered since a shortage of propofol and midazolam due to the coronavirus pandemic occurred.

Key Points: 
  • PAION was contacted by the San Raffaele Hospital as to whether remimazolam could be delivered since a shortage of propofol and midazolam due to the coronavirus pandemic occurred.
  • PAION will fulfill the request from the hospital and will deliver the material free of charge.
  • Remimazolam has received marketing authorization in Japan, and marketing approval applications have been submitted inter alia in the U.S. and in Europe.
  • In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation.

Free 3D Virtual Software from Virtual Heroes Provides 1st Responders, Health Care Workers with Sedation and Airway Management Training

Retrieved on: 
Tuesday, April 7, 2020

Healthcare workers are on the front lines of the battle with the ongoing coronavirus outbreak.

Key Points: 
  • Healthcare workers are on the front lines of the battle with the ongoing coronavirus outbreak.
  • HumanSim: Sedation and Airway is designed to help medical staff gain experience and improve quality of care, by coupling an immersive training environment with an advanced real-time physiology engine.
  • The downloadable, PC-based software training program allows physicians, nurses, medics and other emergency personnel to practice Rapid Sequence Induction (RSI) and Moderate Sedation, techniques for quickly sedating and intubating patients.
  • Visit https://youtu.be/OlfD8NuLwWY for a software overview and then go to http://www.virtualheroes.biz/breathe to download this trainer and reference materials today.

Sedana Medical Donates AnaConDa to Hospitals in Wuhan, China

Retrieved on: 
Thursday, February 27, 2020

STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.

Key Points: 
  • STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.
  • Sedana Medical is a pioneer in making volatile anaesthetics available to critically ill mechanically ventilated patients via the medical device AnaConDa.
  • To begin with, we will donate 300 AnaConDa and related accessories to evaluate the effects of inhalation sedation with AnaConDa on severely ill Corona virus infected patients."
  • Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanicallyventilated patients.

Sedana Medical Donates AnaConDa to Hospitals in Wuhan, China

Retrieved on: 
Thursday, February 27, 2020

STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.

Key Points: 
  • STOCKHOLM, Feb. 27, 2020 /PRNewswire/ --Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.
  • Sedana Medical is a pioneer in making volatile anaesthetics available to critically ill mechanically ventilated patients via the medical device AnaConDa.
  • To begin with, we will donate 300 AnaConDa and related accessories to evaluate the effects of inhalation sedation with AnaConDa on severely ill Corona virus infected patients."
  • Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanicallyventilated patients.

Pipeline Review for Sedation - H1, 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 30, 2020

The latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Pipeline Review, H1 2020, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Key Points: 
  • The latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Pipeline Review, H1 2020, provides an overview of the Sedation (Central Nervous System) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Sedation - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Conformal Medical Announces First Left Atrial Appendage Closures Performed Under Conscious Sedation with its CLAAS Technology at AF Symposium 2020

Retrieved on: 
Wednesday, January 22, 2020

NASHUA, N.H., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Conformal Medical, Inc. announced today the presentation of the first left atrial appendage closure (LAAC) cases with its unique CLAAS Technology in patients under conscious sedation without general anesthesia.

Key Points: 
  • NASHUA, N.H., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Conformal Medical, Inc. announced today the presentation of the first left atrial appendage closure (LAAC) cases with its unique CLAAS Technology in patients under conscious sedation without general anesthesia.
  • Petr Neuzil and Vivek Reddy will present ICE-Guided Implantation of the Conformal Left Atrial Appendage Closure Device: First Clinical Report at the AF Symposium meeting in Washington, D.C., January 23-24.
  • These first procedures using the conscious sedation protocol were successfully performed at Homolka Hospital in Prague, Czech Republic.
  • Conformal Medical, Inc. is a medical device company founded in 2016 to develop devices to prevent stroke in patients with atrial fibrillation.

Last Patient Included in Sedana Medical's Pivotal IsoConDa Study

Retrieved on: 
Monday, January 13, 2020

STOCKHOLM, Jan. 13, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study.

Key Points: 
  • STOCKHOLM, Jan. 13, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study.
  • Thus, all 300 patients have been included and the study is expected to show top-line results during Q2 2020.
  • The IsoConDa study is a pivotal clinical phase III study aimed at getting the drug candidate IsoConDa (isoflurane) approved for inhaled sedation in intensive care in Europe.
  • A major pivotal study is currently ongoing to obtain market approval in Europe for inhaled sedation in intensivecare units with the pharmaceutical IsoConDa (isoflurane).

Last Patient Included in Sedana Medical's Pivotal IsoConDa Study

Retrieved on: 
Monday, January 13, 2020

STOCKHOLM, Jan. 13, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study.

Key Points: 
  • STOCKHOLM, Jan. 13, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study.
  • Thus, all 300 patients have been included and the study is expected to show top-line results during Q2 2020.
  • The IsoConDa study is a pivotal clinical phase III study aimed at getting the drug candidate IsoConDa (isoflurane) approved for inhaled sedation in intensive care in Europe.
  • A major pivotal study is currently ongoing to obtain market approval in Europe for inhaled sedation in intensivecare units with the pharmaceutical IsoConDa (isoflurane).

In-Office General Anesthesia Increases Comprehensive Pediatric Dental Care

Retrieved on: 
Thursday, January 9, 2020

Often, pediatric dental cases will be sent to the hospital operating room to be done under general anesthesia, which requires longer wait times and a higher expense.

Key Points: 
  • Often, pediatric dental cases will be sent to the hospital operating room to be done under general anesthesia, which requires longer wait times and a higher expense.
  • The idea of providing in-office general anesthesia (IOGA) attempts to combat this issue and offer complete comprehensive oral health care to pediatric patients in a faster, more comfortable and less expensive capacity.
  • Not only does the completion of cases improve dramatically, but the number of radiographs and full dental examinations as well, which gives the necessary comprehensive oral health care to pediatric patients.
  • Full text of the article, "Impact of Instituting General Anesthesia on Oral Sedation Care in a Tertiary Care Pediatric Dental Clinic," Anesthesia Progress, Vol.

Global Dental Manufacturing Market Analysis By Product Type, Company Profiles, Regions and Forecasts 2019-2024 - ReportsnReports

Retrieved on: 
Tuesday, December 24, 2019

Advanced technologies such as introduction of robotics and artificial intelligence by various companies like Straumann and rise in demand for innovative devices such as electrosurgical equipment and dental lasers involving non-invasive procedures that require no sedation, surgery or hospital stay likely to facilitate the dental manufacturing market.

Key Points: 
  • Advanced technologies such as introduction of robotics and artificial intelligence by various companies like Straumann and rise in demand for innovative devices such as electrosurgical equipment and dental lasers involving non-invasive procedures that require no sedation, surgery or hospital stay likely to facilitate the dental manufacturing market.
  • Global Dental Manufacturing Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)